Brief: 180 Life Sciences And University Of Oxford Announce Publication Of Positive Phase 2B Dupuytren's Disease Study Results In Lancet Rheumatology

Forum Markets,

29/04/2022 23:37

April 29 (Reuters) - 180 Life Sciences Corp  ATNF.O :
    * 180 LIFE SCIENCES AND UNIVERSITY OF OXFORD ANNOUNCE
PUBLICATION
OF POSITIVE PHASE 2B DUPUYTREN’S DISEASE STUDY RESULTS IN THE
LANCET RHEUMATOLOGY
    * SAYS STUDY ACHIEVED PRIMARY ENDPOINT OF REDUCTION IN
NODULE
HARDNESS AT 12 MONTHS
    * TREATMENT ARM SHOWED THAT NODULES CONTINUED TO SOFTEN AND
REGRESS AT 18-MONTH FOLLOW UP, NINE MONTHS AFTER FINAL DOSE
    * STUDY ACHIEVED SECONDARY ENDPOINT OF REDUCTION IN NODULE
SIZE AT
MULTIPLE TIME POINTS INCLUDING 12 MONTHS
    * THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS IN
THE
TRIAL

Source text for Eikon:  ID:nGNX1SMk2J 
Further company coverage:  ATNF.O 

 ((Reuters.Briefs@thomsonreuters.com;))